Liposomal Irinotecan and Apatinib in ES-SCLC

This study is testing a combination of two cancer drugs — liposomal irinotecan (a chemotherapy) and apatinib (a drug that cuts off blood supply to tumors) — in people with extensive-stage small cell lung cancer (ES-SCLC) that has stopped responding to earlier treatments. **You may be eligible if...** - You are between 18 and 75 years old - You have extensive-stage small cell lung cancer - You have already received one or two lines of treatment and they are no longer working - You have at least one measurable tumor - Your expected survival is at least 12 weeks **You may NOT be eligible if...** - You have previously received drugs that block blood vessel growth (anti-angiogenic drugs like apatinib, bevacizumab, anlotinib, or similar) - You have an active or uncontrolled serious infection - You have difficulty swallowing oral medication, or have chronic nausea, vomiting, or bowel obstruction Talk to your doctor to see if this trial is right for you.